Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules

A Körner1,3, G Mudduluru1,3, C Manegold2 and H Allgayer6,1
1Department of Experimental Surgery Mannheim/Molecular Oncology of Solid Tumors (German Cancer Research Center-DKFZ-Heidelberg), Mannheim Medical Faculty, Ruprecht-Karls-University Heidelberg, Mannheim 68167, Germany; 2Interdisciplinary Thoracic Oncology, Department of Surgery, Medical Faculty Mannheim, University Heidelberg, Mannheim: 68167, Germany

BACKGROUND: Enzastaurin (Enz) is a serine/threonine kinase inhibitor blocking protein kinase C (PKC)β/α/AKT pathway. However, an ability of this compound to inhibit cancer invasion and metastasis is not yet clearly elucidated.

METHODS: The ability of Enz to inhibit invasion and metastasis, and to target molecules was investigated in non-small cell lung cancer (NSCLC) by RT–PCR validated microarray, Matrigel, and in vivo chorionallantoic membrane (CAM) assays.

RESULTS: Enzastaurin significantly reduced migration, invasion, and in vivo metastasis to lungs and liver (CAM assay) of diverse NSCLC cell lines. Genes promoting cancer progression (u-PAR, VEGF, and HIF1α) and tumour suppression (VHL, RASSF1, and FHIT) of NSCLC were significantly (P<0.05) down- or upregulated after Enz treatment in H460, A549, and H1299 cells, respectively. Luciferase/chromatin immunoprecipitation analysis showed that Enz transcriptionally controls urokinase-type plasminogen activator receptor (u-PAR) expression by promoter inhibition through Sp1, Sp3, and c-Jun(AP-1). Moreover, siRNA knockdown of u-PAR re-sensitised Enz-resistant cells and induced apoptosis, suggesting u-PAR as a marker of Enz resistance.

CONCLUSION: This study shows that Enz inhibits migration, invasion, and in vivo metastasis by targeting u-PAR, besides further targeting progression-related and tumour-suppressor genes in NSCLC. Together with u-PAR being a novel putative marker of Enz response, these data encourage molecularly tailored clinical studies on Enz in NSCLC therapy.

Keywords: enzastaurin; u-PAR; RASSF1; FHIT; invasion and metastasis

Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancer cases and is the leading cause of tumour-related death (Jemal et al, 2005; Gridelli et al, 2007). Progression stages and metastasis being the most frequent cause for the high NSCLC lethality. Protein kinase C (PKC) isoforms have been shown to be highly expressed in NSCLC as compared to lung epithelial cells (Clark et al, 2003). Activation of these isoforms contributes to patient survival, proliferation, and the malignant progression of human cancers including breast carcinoma (Ali et al, 2009), B-cell lymphoma (Shipp et al, 2002), glioblastoma (da Rocha et al, 2002), and colorectal carcinoma (Gokmen-Polar et al, 2001). Protein kinase C signalling, which functions through serine/threonine kinase activity, is involved in tumour-induced angiogenesis, tumour growth, differentiation, cytokine secretion, migration, and apoptosis, and is a prominent target for anticancer therapy (Carducci et al, 2006). Protein kinase C activation can trigger ERK and PI3K/AKT pathways, promoting cell proliferation and apoptosis (Balendran et al, 2000; Goekjian and Jirousek, 2001). Moreover, both PKC and AKT phosphorylate glycogen synthase kinaseβ (GSK3β) at Ser9, supporting the notion that these signalling pathways overlap (Fang et al, 2002).

Enzastaurin (Enz), an acyclic bisindolylmaleimide, was initially developed as a specific inhibitor of PKCβ/α (Faul et al, 2003). In addition to this major target, Enz also inhibits other PKC isoforms (δ, γ, ε, and η) (Graf et al, 2005). Enzastaurin was initially developed for anti-angiogenic cancer therapy (Keyes et al, 2002), and recent preclinical studies have shown that Enz exerts prosapoptotic, growth inhibitory, and anti-angiogenic properties in a variety of human cancers (Keyes et al, 2002; Graff et al, 2005; Querfeld et al, 2006; Willey et al, 2009). Moreover, in clinical studies, Enz was well tolerated and has shown encouraging activity in a variety of tumours (Carducci et al, 2006; Watkins et al, 2006; Hanauske et al, 2009). Enzastaurin was shown to target the PI3K/AKT pathway, to inhibit GSK3β and ribosomal protein S6 phosphorylation, to decrease the expression of VEGF (Keyes et al, 2002; Graff et al, 2005) and also to show a synergism with SU1174 and pemetrexed (Tekle et al, 2008; Faoro et al, 2009; Giovannetti et al, 2010).

Tumour progression is a multistep process including uncontrolled growth, invasion, and metastasis (Douglas and Robert, 2000), which, to a considerable part, is mediated through an abnormal regulation and function of genes. Several studies have analysed the involvement of individual genes (Müller-Tidow et al, 2001; Marchetti et al, 2002; Werle et al, 2004), gene expression differences between cell lines (Chen et al, 2001; Gemma et al, 2001), and gene expression differences between primary tumours and normal lung tissues in this context (Bhattacharjee et al, 2001; Hellmann et al, 2001; Beer et al, 2002; Heighway et al, 2002; Wikman et al, 2002; Zochbauer-Muller et al, 2002; Borczuk et al, 2002).
Materials, cell lines, and reagents

Enzastaurin (in DMSO) was a generous gift from Eli Lilly (Indianapolis, IN, USA). All cell lines (H460, LXF289, A427, H1395, A549, and H1299) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in ATCC-recommended medium (10% FBS, 37 °C, 5% CO2). Fertilised special pathogen-free eggs were from Charles River (Hilden, Germany). Antibodies used for supershift/chromatin immunoprecipitation analysis (ChIP) experiments were from Santa Cruz Biotechnology (Santa Cruz, CA, USA): p-c-Jun (sc-8224), JunD (sc-74xs), JunB (sc-54x), c-Fos (sc-52x), FosB (sc-7203x), Fra-1 (sc-22794x), Fra-2 (sc-604x), Sp1 (sc-59x), Sp3 (sc-644x), and unspecific IgG (sc-2338).

Western blot antibodies against phospho-PKC(PAN) (Santa Cruz, CA, USA): p-c-Jun (sc-822x), JunD (sc-74x), JunB (sc-54x), c-Fos (sc-52x), FosB (sc-7203x), Fra-1 (sc-22794x), Fra-2 (sc-604x), Sp1 (sc-59x), Sp3 (sc-644x), and unspecific IgG (sc-2338).

VHL, RASSF1, and FHIT antibodies were used for supershift/chromatin immunoprecipitation experiments. ChIP was performed as previously described (Mudduluru and Allgayer, 2008). The u-PAR antibodies were a generous gift from Dr. Bob Trent (Indiana University School of Medicine, Indianapolis, IN, USA). All u-PAR antibodies were used at 1:200 dilution and were positive in a Western blot against u-PAR (Hs00182181; Applied Biosystems, Carlsbad, CA, USA).

MATERIALS AND METHODS

Materials

Enzastaurin (in DMSO) was a generous gift from Eli Lilly (Indianapolis, IN, USA). All cell lines (H460, LXF289, A427, H1395, A549, and H1299) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in ATCC-recommended medium (10% FBS, 37 °C, 5% CO2). Fertilised special pathogen-free eggs were from Charles River (Hilden, Germany). Antibodies used for supershift/chromatin immunoprecipitation analysis (ChIP) experiments were from Santa Cruz Biotechnology (Santa Cruz, CA, USA): p-c-Jun (sc-8224), JunD (sc-74xs), JunB (sc-54x), c-Fos (sc-52x), FosB (sc-7203x), Fra-1 (sc-22794x), Fra-2 (sc-604x), Sp1 (sc-59x), Sp3 (sc-644x), and unspecific IgG (sc-2338).

Western blot antibodies against phospho-PKC(PAN) (Santa Cruz, CA, USA): p-c-Jun (sc-822x), JunD (sc-74x), JunB (sc-54x), c-Fos (sc-52x), FosB (sc-7203x), Fra-1 (sc-22794x), Fra-2 (sc-604x), Sp1 (sc-59x), Sp3 (sc-644x), and unspecific IgG (sc-2338).

 Luciferase reporter assay

Cells were transiently transfected with 500 ng of −398/+51 u-PAR WT/Sp1- or AP1-mutant plasmid, or with pGL3 basic (Allgayer et al., 1999), and 50 ng of Renilla-luciferase plasmid as a transfection control using Effectene (Qiagen, Hilden, Germany).

After treatment, cells were treated with DMSO or Enz for another 24 h, and reporter assays performed using the Dual-Luciferase reporter assay system (Promega).

Real-time PCR

Total RNA isolation and cDNA synthesis was performed as described (Mudduluru and Allgayer, 2008). The u-PAR (Hs00182181; Applied Biosystems, Carlsbad, CA, USA) mRNA was quantified using TaqMan Universal PCR Master Mix and β-Actin (Human ACTB 4333762F; Applied Biosystems) as housekeeping gene. Quantification of HIF-1α, VEGF, FHIT, Sp1, Sp3, and c-Jun mRNA was performed using SYBR Green-PCR-Master-Mix (Applied Biosystems). Relative expression was calculated by the 2^(-ΔΔCt) method, where ΔΔCt = ΔCt(experimental) - ΔCt(control).
of these genes was calculated by the \( 2^{-\Delta\Delta CT} \) method. Primer sequences are provided in Supplementary Table 1.

ELISA and western blotting

ELISA and western blot analysis were performed as described (Leupold et al., 2007; Mudduluru and Allgayer, 2008). In brief, for ELISA, cells were either treated with DMSO or with Enz for 24 h. For western blot analysis, cells were serum starved for 24 h and treated with DMSO or Enz for another 24 h. Cells were stimulated with EGF (100 nM) for 15 min. Cells were washed twice with ice-cold PBS and lysed with lysis buffer (Biosource, Camarillo, CA, USA). Protein concentration was determined by BCA (Pierce, Rockford, IL, USA). The u-PAR protein was assayed using the Imubind-u-PAR-ELISA kit (American Diagnostica, Hauppauge, NY, USA).

Transfection of si-uPAR

si-u-PAR (ID289377; Ambion, Austin, TX, USA) was used to knockdown the expression of u-PAR. A nonspecific siRNA (scrambled) served as a negative control. Sh-RNA vectors of sh-u-PAR (RHS4430-99290516), and non-silencing control (RHS4346) were purchased from Open Biosystems (Huntsville, AL, USA). A549 and H1299 cells were transiently transfected using RNAiFect or Effectene, respectively (Qiagen). At 24 h after transfection, cells were used for MTT and Matrigel assays as described.

Apoptosis assays

Cells (1 x 10^6 per ml) were treated with Enz (as the respective IC50 values) and harvested after 48 h either with or without transfections. Apoptosis induction by Enz was measured by the FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen, San Diego, CA, USA) as described (Querfeld et al., 2006). According to the manufacturer’s instructions, cells were incubated with 5 \( \mu \)l per test FITC-conjugated annexin V in the presence of 5 \( \mu \)l per test PI, and further screened by flow cytometry (BD Biosciences, San Diego, CA, USA). Annexin V-positive PI-positive cells correspond to apoptotic cells and are represented as a percent of apoptotic cells against DMSO-treated cells.

Electrophoretic mobility shift and ChIP assay

Gel shifts were performed as described (Mudduluru and Allgayer, 2008), using 5 \( \mu \)g of nuclear extract of DMSO- or Enz-treated (IC50, 24 h) A549 cells. Chromatin immunoprecipitation was performed according to the manufacturer’s protocol (Upstate, Lake Placid, NY, USA) as described (Leupold et al., 2007; Mudduluru and Allgayer, 2008), with 2 \( \mu \)g specific (Sp1, Sp3, and p-c-Jun) and nonspecific IgG overnight, using aliquots of precleared lysates. DNA was purified and eluted with 100 \( \mu \)l elution buffer (Qiagen reaction purification kit). PCR was performed according to Leupold et al. (2007), for region \(-190/-171\) (u-PAR-AP1). Amplification of region \(-152/-135\) (u-PAR-SP1/SP3/SP3/2x-like) was performed by SYBR Green Master Mix, with the specific primers:

For: 5’-AGGCATCTGGGACAGAG-3’ and Rev 5’-GGACTCCCTCCAGACATTTT-3’. Chorionallantoic membrane assay

The chorionallantoic membrane (CAM) assay was performed as described (Leupold et al., 2007), with few modifications. Briefly, 2 x 10^6 cells were inoculated on the CAM of 10-day-old chicken embryos. On days 12 and 14, chicken embryos were treated intravenously with different concentrations of Enz (2 or 4 \( \mu \)M) or DMSO, respectively. Untreated embryos served as a control. On day 16, the embryos were killed. Metastasis was determined by harvesting lungs and liver, and processing the tissue for genomic human DNA by quantitative alu-PCR.

Statistical analysis

Statistical significance of differences between Enz- vs DMSO-treated samples was calculated with the Student’s t-test (\( P \leq 0.05 \) was considered as statistically significant, \( P \leq 0.1 \) as a trend).

RESULTS

Enzastaurin inhibits the growth of human NSCLC cells

Six human NSCLC cell lines were tested for their sensitivity to Enz regarding proliferation (Figure 1A). Large cell-type H460 and adenocarcinoma LXF289 cells showed the highest sensitivity. A moderate response was observed in H1395 (adenocarcinoma) and A427 (squamous carcinoma) cells, whereas A549 (squamous carcinoma) and H1299 (adenocarcinoma) cells showed comparatively more resistance to Enz. Mean IC50 values of the cells are presented in the box in Figure 1A. Similarly, viable cells were counted after Enz treatment, confirming the IC50 concentrations determined by MTT assays (data not shown). Next, to determine if the calculated IC50 concentrations of Enz were able to induce apoptosis and inhibit the known target molecules of Enz, apoptotic assays and western blot analysis were performed. H460, A549, and H1299 cells were treated for 48 h with their respective IC50 concentrations. Enzastaurin (IC50 concentrations) induced apoptosis of H460, A549, and H1299 cells compared with the DMSO-treated samples was shown in Figure 1B. Because EGFr-induced signalling represents a major pathway driving NSCLC progression, we in addition sought to investigate the ability of Enz to inhibit essential target molecules following EGF stimulation. H460, A549, and H1299 cells were pretreated either with DMSO, or with Enz, for 24 h, and stimulated, or unstimulated, with EGF (100 nmol l^-1) for 15 min before harvesting the cells. As results, we found that Enz treatment can inhibit the phosphorylation of PKC, AKT, p42/44, and GSK3\( \beta \) both in the presence and in the absence of EGF (Figure 1C, Supplementary Figure 1).

Enzastaurin affects cell migration and invasion

To determine whether Enz affects the migration and invasion of NSCLC cells in vitro, we evaluated the migratory (wound-healing assay) and invasive (Transwell in vitro invasion assay) capacity of H460, A549, and H1299 cells, after treatment. Enzastaurin- or Enz/EGF-treated cells displayed a significantly reduced migration and invasion as compared to DMSO- and EGF-stimulated control cells; respectively (\( P < 0.02 \); Figure 1D), showing that Enz inhibits EGFr-induced cell migration and invasion in addition to spontaneous invasion in NSCLC. This prompted further experiments to study changes in gene expression upon Enz treatment, to delineate major target molecules mediating Enz-inhibited invasion.

Analysis of gene expression changes after Enz treatment

To analyse changes in gene expression after Enz treatment, we applied Illumina Human Sentrix-8 BeadChip assays. A549 cells were either treated with DMSO, or with Enz, for 24 or 48 h at the same concentration as used for inhibiting invasion. Total RNA was isolated, labelled, and hybridised to the arrays. After 24 h, 1255 genes (616 up, 639 down), and after 48 h, 2711 genes (1477 up, 1234 down) were significantly (\( \geq 1.5 \)-fold) deregulated after Enz treatment (Supplementary Tables 2 and 3), respectively. Comparing our microarray results with data present in the literature, we found that a considerable number of genes that have been described to be either up- or downregulated specifically in NSCLC in previous publications were significantly altered upon Enz treatment (Table 1). These genes include genes regulating cell proliferation, structure, adhesion, migration, invasion, or angiogenesis, or are cell-cycle regulators. We found that all of these
Enz inhibits invasion and metastasis in NSCLC

A Kämmer et al.

British Journal of Cancer (2010) 103(6), 802 – 811

Cell adhesion, cell structure, and signal transduction

Other genes

| Gene symbol | Accession no. | Fold change (Enz 24/48 h vs DMSO) | Reference |
|-------------|---------------|----------------------------------|-----------|
| TOP 2A      | NM_001067     | -3.8                              | Hellmann et al. 2001; Wilman et al. 2002 |
| SLC1A5      | NM_005628     | +2.1                              | Wilman et al. 2002 |
| ABC3        | NM_020337     | -5.0                              | Wilman et al. 2002 |

Figure 1 Enzastaurin inhibits NSCLC proliferation, migration, and invasion. (A) Cell proliferation of NSCLC after Enz treatment. Data are expressed as the percentage of control (treated with DMSO) cells. Points, mean ± s.d. of three experiments. Resulting IC_{50} values for Enz for all NSCLC cell lines investigated are represented in the box. (B) Apoptosis analysis of H460, A549, H1299 after Enz treatment. After 48 h of Enz treatment, cells were screened by flow cytometry and percent of apoptotic cells was calculated against DMSO-treated cells. (C) Western blot analysis of cells treated with EGF, Enz, or with the combination of both agents. Specific antibodies against the indicated molecules were used, together with anti-beta-Actin as a loading control. (C and D) Percentage of migrating cells (wound-healing assay) and invading cells (Matrigel assay). Cells were treated as described in the Materials and Methods section. DMSO-treated samples served as a control (100%), and other treated samples were calculated and plotted as a percentage of this value. *p<0.05.

Table 1 Enz inversely regulates relevant genes reported for NSCLC.

| Gene symbol | Accession no. | Fold change (Enz 24/48 h vs DMSO) | Reference |
|-------------|---------------|----------------------------------|-----------|
| COND1       | NM_053056     | -5.1                              | Borczuk et al. 2003 |
| SI10P       | NM_005980     | -2.3                              | Beer et al. 2002 |
| MCM 2       | NM_004526     | -2.1                              | Wilman et al. 2002 |
| CEACAM1     | NM_0010249    | -4.2                              | Bhattacherjee et al. 2001 |
| PRSS3       | NM_002771     | -2.4                              | Diederichs et al. 2004 |
| PLA2G1      | NM_002658     | -2.2                              | Chen et al. 2001 |
| PLAU        | NM_1005376    | -1.8                              | Werle et al. 2004; Hayes et al. 2006 |
| ERBB3       | NM_001982     | -7.4                              | Beer et al. 2002 |
| FGFR3       | NM_000142     | -4.7                              | Hellmann et al. 2001 |
| HIF1α       | NM_001530     | -13                               | Hayes et al. 2006 |
| IFNGR3      | NM_0510133    | -2.4                              | Beer et al. 2002; Hellmann et al. 2001; Wilman et al. 2002 |
| GADD45A     | NM_001924     | +9.6                              | Hellmann et al. 2001 |

Cell cycle, proliferation, migration, and angiogenesis

| Gene symbol | Accession no. | Fold change (Enz 24/48 h vs DMSO) | Reference |
|-------------|---------------|----------------------------------|-----------|
| KRT18       | NM_005556     | -1.7                              | Beer et al. 2002 |
| KRT18       | NM_002264     | -2.6                              | Wilman et al. 2002 |
| MUC1        | NM_0010180    | -2.1                              | Borczuk et al. 2003 |
| VEGFC       | NM_005429     | -2.4                              | Borczuk et al. 2003 |
| FGFR1       | NM_000509     | -3.5                              | Diederichs et al. 2004 |
| S100P        | NM_000142     | -2.4                              | Borczuk et al. 2003 |
| IFNGR3      | NM_0010133    | -13                               | Hellmann et al. 2001 |
| PLEC1       | NM_211284     | +2.4                              | Hellmann et al. 2001 |

Tumor suppressor

| Gene symbol | Accession no. | Fold change (Enz 24/48 h vs DMSO) | Reference |
|-------------|---------------|----------------------------------|-----------|
| FHIT        | NM_002012     | +5.0                              | Zachbauer-Muller et al. 2002 |
| RASSF1      | NM_007182     | +2.0                              | Zachbauer-Muller et al. 2002 |
| VHL         | NM_000551     | +1.7                              | Hayes et al. 2006 |

Other genes

| Gene symbol | Accession no. | Fold change (Enz 24/48 h vs DMSO) | Reference |
|-------------|---------------|----------------------------------|-----------|
| TOP 2A      | NM_001067     | -3.8                              | Hellmann et al. 2001; Wilman et al. 2002 |
| SLC1A5      | NM_005628     | +2.1                              | Beer et al. 2002 |
| ABC3        | NM_020337     | -5.0                              | Beer et al. 2002 |

© 2010 Cancer Research UK
Enzastaurin inhibits u-PAR gene expression in NSCLC cells

The u-PAR has been reported to be one of the major metastasis-related genes being overexpressed in many cancer types, and also in NSCLC (Beer et al., 2002; Werle et al., 2004). Previous reports including our own have shown that an overexpression of this receptor is associated with a high invasive and metastatic capacity of NSCLC, and also EGF-induced, NSCLC cells, among other cancer types (Nikolova et al., 2009). Therefore, we decided to specifically analyse a putative function of the u-PAR in Enz-regulated invasion, and molecular mediators addressed by Enz to regulate u-PAR in NSCLC. ELISA showed a significant reduction of u-PAR protein after Enz treatment in H460 (P = 0.0021), A549 (P = 0.02), and H1299 (P = 0.0022) cells as compared to the DMSO-treated samples (Figure 4A), in addition to the downregulation of u-PAR mRNA observed in the same cell lines in the previous section. It has been well reported that u-PAR gene expression in malignants cells is largely because of the transcriptional regulation of the gene (Allgayer et al., 1999; Laufs et al., 2006; Leupold et al., 2007). Specifically, it has been reported that the u-PAR promoter, to a major part, is being regulated by transcription factors of the AP-1 and Sp family (Allgayer et al., 1999; Laufs et al., 2006; Leupold et al., 2007). Correspondingly, we found that Enz treatment in A549 and H1299 cells significantly downregulated the expression of Sp1-, Sp3-, and c-Jun-transcription factors (P < 0.05; Supplementary Figure 2), which have been reported previously to be major regulators of u-PAR promoter activity. In luciferase assays of H460, A549, and H1299 cells transfected with a reporter plasmid driven by the −398/+51 upstream region of the u-PAR gene, we found a significant reduction in u-PAR wild-type promoter activity after Enz treatment (P = 0.008) (Figure 4B). Moreover, siRNA-mediated mutagenesis abolishing the binding of either Sp- or AP-1-family members to their respective binding sites within the u-PAR promoter abolished the ability of Enz to induce a further reduction of promoter activity of the respective construct (Figure 4C). This was paralleled by a specific reduction of the binding of either Sp1, Sp3, or AP-1-family members to their specific cis elements within the u-PAR promoter in EMSA analysis (Supplementary Figure 3b and c), which could also be observed for the situation of EGF-induced A549 cells (Supplementary Figure 3a). Finally, to show that Enz is able to regulate transcription factor binding to the natural u-PAR promoter, we performed ChIP analysis for the endogenous u-PAR upstream region. Chromatin immunoprecipitation revealed significantly less binding of especially Sp1, and phospho-c-Jun, to the endogenous u-PAR promoter after Enz treatment (Figure 4D, Supplementary Figure 3d). Taken together, data suggest that Enz inhibits the expression of the u-PAR, at least to a relevant part by suppressing u-PAR promoter activity, by downregulation of the binding of especially Sp1, and c-Jun out of the AP-1 family.

u-PAR knockdown re-sensitises NSCLC cells and induces apoptosis to Enz

A427, A459, and H1299 are relatively resistant to Enz treatment as compared to other NSCLC cell lines. This observation supported the notion that endogenous u-PAR gene expression might be associated with resistance to Enz. Therefore, we conducted specific knockdown experiments with an siRNA/sh-RNA against endogenous u-PAR, the efficient knockdown of endogenous u-PAR being confirmed with u-PAR-ELISA (Supplementary Figure 4a and b). We observed that A549 and H1299 cells treated with si-u-PAR/sh-u-PAR were significantly re-sensitised to Enz (A549/IC_{50} = 7.0 μM; H1299/IC_{50} = 9.0 μM) when compared to scrambled control-transfected cells (A549/IC_{50} = 10 μM; H1299/IC_{50} = 12 μM) (Figure 4E). Similarly, viable cells were counted after Enz treatment either with scrambled/sh-RNA or with si-u-PAR/sh-u-PAR knockdown, which confirmed the IC_{50} concentrations determined by MTT assay (data not shown). Furthermore, u-PAR knockdown cells significantly induced apoptosis when compared with control cells after 48 h of Enz treatment (Figure 4F), and also showed a further decrease in u-PAR protein
levels after Enz treatment (Supplementary Figure 4a and b). These data suggest that u-PAR might be one molecular parameter indicating Enz resistance of NSCLC cells.

Enzastaurin reduces distant metastasis of NSCLC cells in vivo

Our previous results suggested that Enz reduces migration and invasion in vitro. To strengthen these observations, we used the chicken embryo metastasis assay (CAM) (Leupold et al., 2007) to check the ability of Enz to inhibit the formation of distant metastasis in vivo. Towards this end, H460, A549, and H1299 cells were inoculated on the upper CAM of 10-day-old chicken embryos. On day 12 and 14, the embryos were treated intravenously with 2 or 4 μM of Enz, or equal concentrations of DMSO, respectively. On day 16, the embryos were killed, lungs and livers harvested for DNA, and the number of cells metastasised into livers and lungs were measured with a TaqMan-based PCR amplifying human alu-sequences on the chicken background (Leupold et al., 2007). As a result, we found that Enz was able to reduce the formation of distant metastasis significantly in H460 (liver $P = 0.001$, lungs $P = 0.003$), A549 (liver $P = 0.037$, lungs $P \leq 0.01$), and H1299 (liver $P = 0.02$, lungs $P = 0.05$) cells when compared with their respective DMSO controls (Figure 5A–C). These data suggest that Enz, besides migration and invasion, inhibits in vivo metastasis of three NSCLC cell lines.

DISCUSSION

This is the study to show that Enz inhibits migration, invasion, and in vivo metastasis in NSCLC, and to explore first mechanisms contributing to Enz-induced inhibition of migration, invasion, and metastasis-related processes in NSCLC. We show that Enz transcriptionally inhibits u-PAR gene expression, downregulates the tumour progression-related molecules HIF1α and VEGFC, and also upregulates the tumour-suppressor genes VHL, RASSF1, and FHIT. Furthermore, our findings suggest that an si-u-PAR/sh-u-PAR knockdown sensitises resistant NSCLC cells to Enz and induces apoptosis. These findings suggest that Enz treatment in NSCLC patients might contribute to enhancing their survival by inhibiting genes of tumour progression and by inducing tumour-suppressor genes.

Enzastaurin was initially developed as a specific inhibitor of PKCβ, also inhibiting the other PKC isoforms (δ, ε, η, and γ), PI3K/AKT, GSK3β, and S6K (Faul et al., 2003; Graff et al., 2005; Tekle et al., 2008; Faoro et al., 2009; Willey et al., 2009; Giovannetti et al., 2010). In agreement with previous studies, our initial observations
Figure 4 Enzastaurin inhibits u-PAR promoter activity and u-PAR protein expression. (A) Total amounts of u-PAR protein as evaluated by ELISA as described in the Materials and Methods section. Each value represents the average of triplicate measurements. (B) Luciferase activity assay for H460, A549, and H1299 cells. Data are presented as the mean ± s.d. of three independent experiments performed in quadruplicate. (C) Luciferase activity assay of A549 cells transfected with wild-type (wt) u-PAR promoter, and Sp/AP1 binding site mutated reporter constructs. Values represent the mean of three independent experiments performed in triplicate; bars, s.d. (D) Real-time PCR quantification of u-PAR promoter binding after chromatin immunoprecipitation (ChIP) with Sp1, Sp3, p-c-Jun, or IgG antibodies in the presence, or absence, of Enz (24 h). (E and F) Cell viability (MTT) and apoptosis assay. At 24 h after transfection with si-u-PAR/sh-u-PAR, cells were treated with Enz for 48 h and the results compared to DMSO-treated controls for MTT assay, represented as percentage and for apoptosis cell were screened by flow cytometry and percent of apoptotic cells were calculated against to DMSO-treated cells.

in six NSCLC cell lines have shown that Enz inhibits cell growth and activation of PKC, p-42/44, AKT, and GSK3β (Faul et al., 2003; Graff et al., 2005). Furthermore, we in addition show that it inhibits the EGF-stimulated activation of these kinases. In addition to initial findings in cultured hepatocellular carcinoma, we now show that Enz inhibits the in vitro migration and invasion of NSCLC cells (Guo et al., 2009), and that EGF-induced invasion is counteracted by Enz, which is a major pathway in NSCLC progression (Nikolova et al., 2009). Correspondingly, PKC isoforms have been shown to be activated in NSCLC cells, and to correlate with tumour progression in different cancers (Shipp et al., 2002; Clark et al., 2003; Ali et al., 2009; Gokmen-Polar et al., 2001). As further fundamental pathways, the MAPK/ERK and PI3K/AKT signalling axis have been reported to be activated upon PKC activation, which leads to cell proliferation and anti-apoptosis (Balendran et al., 2000; Goekjian and Jirousek, 2001). By inhibiting the activation PKC/other Ser/Thr kinases such as AKT, p-42/44, and GSK3β in NSCLC cells, in our gene expression array we now found that Enz(19,874),(983,995)
component of the E3 ubiquitin ligase system (Karhausen et al., 2005). It is an interesting observation of this study that VHL is getting upregulated, and its targeted molecule HIF1α, in addition to VEGF that is transactivated by HIF1α, is getting downregulated upon Enz treatment. Correspondingly, previous reports have suggested these genes to be inversely regulated in NSCLC (Forsythe et al., 1996; Wang et al., 2009). In addition, u-PA and u-PAR, which are upregulated in NSCLC (Welre et al., 2004; Beyer et al., 2006), are getting downregulated upon Enz treatment in our study. Interestingly, all three of these tumour progression-related genes, u-PA, HIF1α, and VEGF, are either activated by the downstream axis of, or transcriptionally regulated at least in part, by the MAPK/ERK and/or PI3K/AKT pathways (Jo et al., 2003; Tsai et al., 2003; Phillips et al., 2005; Skurk et al., 2005), which are inhibited by Enz treatment (Faul et al., 2003; Graff et al., 2005).

The u-PA is an essential molecule in the context of proteolysis, migration, invasion, and metastasis (Jo et al., 2003; Dass et al., 2008), and its function and transcriptional regulation are well studied (Laufs et al., 2006). Interestingly, in our study, Enz inhibited u-PA promoter activity by inhibiting the gene expression and binding of Sp1, Sp3, and c-Jun(AP-1) to the u-PA-promoter in vitro and in vivo (CHIP). In the context of suppressing u-PA gene expression through Enz, it was an interesting initial observation in our study that the knockdown of u-PA might be able to resensitize relatively resistant NSCLC cells and induces apoptosis after Enz treatment (Querfeld et al., 2006; Lee et al., 2008; Morgillo et al., 2008). This finding emphasises the general importance of defining critical molecular markers that are associated with a potential resistance towards novel targeted therapy compounds, because otherwise it might lead to the treatment of patients that, by their molecular condition, are unable to respond to the novel drug. In fact, this might be one of the explanations as to why initial clinical trials with Enz that were not associated with parallel translational molecular studies at the resected tumour tissue of treated patients, led to initial contradictory results (Casey et al., 2009; Richards et al., 2009; Kreisl et al., 2010; Wick et al., 2010). However, with our results we might give an additional encouragement for the initiation of more tailored-therapy clinical studies, in which putatively essential molecular markers associated with response or resistance are being measured before the decision for a certain combination of therapies in the individual patient.

In our paper, we show that Enz inhibits in vivo distant metastasis to liver and lungs in the CAM assay. Apart from its pro-apoptotic, growth inhibitory, and anti-angiogenic properties (Keyes et al., 2002; Graff et al., 2005; Querfeld et al., 2006; Willey et al., 2009), this could be, at least in part, due to downregulating tumour progression and invasion-related genes (u-PAR, HIF1α, and VEGFC) and upregulating NSCLC tumour-related suppressor genes (HIF1α, RASSF1, and VHL) by Enz. We consider it unlikely that a main mechanism of metastasis inhibition by Enz can be explained by anti-angiogenesis, because we observed that DMSO-or Enz-dipped plugs did not show any significant difference in their effect on the formation of embryonic vasculature of the upper CAM (data not shown). However, certainly, an anti-angiogenic component of Enz in the context of anti-metastatic action in our model cannot be ruled out completely.

Taken together, this is the first comprehensive analysis to investigate differentially regulated genes in NSCLC cells upon Enz treatment, and to implicate novel Enz targets in the context of migration, invasion, and distant metastasis in NSCLC. Our results suggest that Enz has a major role in downregulating the u-PAR through Sp1/Sp3 and c-Jun(AP-1), besides HIF1α and VEGFC that are implicated in tumour growth and metastasis, in parallel to upregulating tumour-suppressors relevant for NSCLC. Furthermore, the knockdown of u-PAR re-sensitises NSCLC cells to Enz treatment. These findings give important information for ongoing clinical trials with Enz in NSCLC patients, and further studies investigating resected tumour tissue or blood samples of Enz treated patients for, for example, u-PAR or serum-soluble u-PAR (Henic et al., 2008), as a potentially clinically relevant marker of therapy resistance are clearly encouraged.

ACKNOWLEDGEMENTS

This project was partly supported by Lilly (Indianapolis, IN, USA). HA was supported by Alfred Krupp von Bohlen und Halbach Foundation (Award for Young Full Professors; Essen), Hella-Bühler-Foundation (Heidelberg), Dr Ingrid zu Solms Foundation (Frankfurt/Main), the Hector Foundation (Weinheim, Germany), the FRONTIER Excellence Initiative of the University of Heidelberg, and the Walter Schulz Foundation (Munich, Germany). This publication contains parts of the dissertation (Dr sc. hum.) of Alexandra Körner at Mannheim Faculty of Medicine, University of Heidelberg, Germany. We thank Dr Bernhard Korn for his support in microarray analysis and Erika Hillerich and Paolo Ceppi for excellent help and critical appraisal of the paper.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES

Ali S, Al-Sukhun S, El-Rayes BF, Sarkar FH, Heilbrun LK, Philip PA (2009) Protein kinases C isozymes are differentially expressed in human breast carcinomas. Life Sci 84: 766 – 771

Allgayer H, Wang H, Gallicc GE, Crabtree A, Mazar A, Aupper M, Jones T, Kraker AJ, Boyd DD (1994) Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream activator motif (-152/-153) bound with Sp1. J Biol Chem 274: 18248 – 18437

Baldenb D, Hare GR, Kleloch A, Williams MR, Alesi DR (2000) Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 484: 217 – 223

Beer DG, Kardia SL, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD (2000) The hallmarks of cancer. Cell 100: 21 – 32

Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Rees CA, Shiroma G, Wilkens LR, Wojcik SE, Shaughnessy FD Jr, Herman JG, Moore SM, Meltzer PS, Ross KN, Yezhanel GR, Trent JM, Loda M, Lander ES, Golub TR, Boguski MS, Lander ES, Mesirov JP (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790 – 13795

Borzuca AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA (2003) Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 163: 1949 – 1960

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Clark AS, West KA, Blumberg PM, Dennis PA (2003) Altered protein expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 9: 816 – 824

Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Bubic R, Jauch KW, Schaldberg FW, Allgayer H (2006) Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 106: 1026 – 1035

Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Behezji J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Winden AS, Johnsons HL, Golub TR, Meyeron S (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790 – 13795

Chen JY, Peck K, Hong TM, Yang SC, Cher YP, Shih JY, Wu R, Cheng JL, Roffler SR, Wu CW, Yang PC (2001) Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 61: 5223 – 5230

Clark AS, West KA, Blumberg PM, Dennis PA (2003) Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemoresistance. Cancer Res 63: 780 – 786

da Rocha AB, Mans DR, Regner A, Schwartsmann G (2002) Targeting tumour suppressor locus 3p21.3 inactivation of a RAS association domain family protein from the lung uPA/uPAR system in human cancers. Cancer Res 62: 6169 – 6174

Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP (2000) Epigenetic inhibition of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream activator motif (-152/-153) bound with Sp1. J Biol Chem 274: 18248 – 18437

Douglas H, Robert AW (2000) The hallmarks of cancer. Cell 100: 21 – 32

Enz inhibits invasion and metastasis in NSCLC A Körner et al

Enz inhibits invasion and metastasis in NSCLC A Körner et al

Enz inhibits invasion and metastasis in NSCLC A Körner et al

ENZ inhibits invasion and metastasis in NSCLC A Körner et al

Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB (2002) Convergence of tumour suppressor locus 3p21.3 inactivation of a RAS association domain family protein from the lung uPA/uPAR system in human cancers. Cancer Res 62: 6169 – 6174

Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Senega GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604 – 4613

Gennia A, Takenaka K, Hosoya Y, Matuda K, Seike M, Kurimoto F, Ono Y, Uematsu K, Takeda Y, Hibiino S, Yoshimura A, Shibuuya M, Kudoh S (2001) Altered expression of several genes in highly metastatic subpopulations of a human adenocarcinoma cell line. Eur J Cancer 37: 1554 – 1561

Giovannetti E, Honeywell R, Hanuske AR, Tekle C, Kuenen B, Sigmund J, Giaccone G, Peters GJ (2010) Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets 11: 12 – 28

Goekjian PG, Irourou MR (2001) Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10: 2117 – 2140

Golmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP (2003) Elevated protein kinase C beta is a palliative factor in colon carcinogenesis. Cancer Res 63: 1375 – 1381

Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Behezji J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Winden AS, Johnsons HL, Golub TR, Meyeron S (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790 – 13795

Guo K, Li Y, Kang X, Sun L, Cui J, Gao D, Liu Y (2009) Role of PKCbeta in hepatocellular carcinoma cells migration and invasion in vitro: a potential therapeutic target. Clin Exp Metastasis 26: 189 – 195

Hanuske AR, Lahn M, Musib L, Weigang-Köhler K, Yilmaz E, Greffe T, Kuenen B, Thornton D, McNealy P, Giaccone G (2009) Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 20b: 1565 – 1575

Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M (2006) Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 24: 4929 – 4939

Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Henic E, Borgfeldt C, Christensen IJ, Cassle´n B, Høyer-Hansen G (2008) Gene-expression profiles predict survival of patients with stage IIIIB/IV non-small cell lung cancer (NSCLC) (Abstract no. 8035). J Clin Oncol 27: 156

Henic E, Borgfeldt C, Christensen IJ, Cassle´n B, Høyer-Hansen G (2008) Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 14: 5785 – 5793

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Cronin KA, Ries LA (2008) Cancer statistics. CA Cancer J Clin 58: 7 – 24

Jorissek MR, Ballas LM, Schotten T, Kahl A, Mohr M (2003) Acyclic N-(aza-cycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 13: 1857 – 1859

Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA (2010) A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol 12: 181 – 189

Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA (2010) A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol 12: 181 – 189
